Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01660984 · ClinicalTrials.gov registry record
Natural History Study of Children and Adults With Medullary Thyroid Cancer
A clinical trial of Medullary Thyroid Cancer, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 259
- Enrollment target
- 1
- Study location
NCT01660984: Recruiting study of Medullary Thyroid Cancer, sponsored by National Cancer Institute (NCI).
NCT01660984 is a study of Medullary Thyroid Cancer that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 259 participants, below the 304-participant average among 4 other Medullary Thyroid Cancer trials with a reported enrollment target (15% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01660984, a study of Medullary Thyroid Cancer, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 259 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Medullary thyroid cancer (MTC) is a rare cancer of the thyroid gland. In children and adults, it is often part of a condition called Multiple Endocrine Neoplasia 2 (MEN2). MEN2 is usually caused by a genetic mutation, and it can cause a number of problems in addition to MTC. These problems include adrenal gland tumors, hormone changes, and problems with the bones and other organs. Not much is known about how MTC develops over time, especially in people with MEN2. Researchers want to study MTC in children and adults and see how it affects their growth and development. Objectives: \- To study how medullary thyroid cancer affects children and adults over time. Eligibility: \- Children and adults who have medullary thyroid cancer. Design: * Participants will be screened with a brief physical exam and medical history. Blood and tissue samples will be collected to see whether participants have the MEN2 genetic mutation. * Treatment will not be provided as part of this study. However, participants will be receiving standard care for MTC. They may be eligible for other clinical trials at the National Institutes of Health. * Participants will have regular study visits every 6 to 12 months to evaluate their MTC and any treatment. Blood tests, imaging studies, and other tests may be performed as needed to monitor the disease. * Participants and their parents/guardians will also complete questionnaires about their health and emotions during the study.
Primary Outcome
Characterized features will be described and presented.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2012-07-30 |
What NCT01660984 shows while recruiting
NCT01660984 is an observational study that tracks outcomes without assigning an intervention. The registered 259 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 4 other Medullary Thyroid Cancer trials with a reported enrollment target (15% lower).
The record links to 1 condition, with Medullary Thyroid Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01660984 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01660984 about?
NCT01660984 is a clinical study titled "Natural History Study of Children and Adults With Medullary Thyroid Cancer". Background: \- Medullary thyroid cancer (MTC) is a rare cancer of the thyroid gland. In children and adults, it is often part of a condition called Multiple Endocrine Neoplasia 2 (MEN2). MEN2 is usually caused by a genetic mutation, and it can cause a number of problems in addition to MTC. These pr...
What is the current status of trial NCT01660984?
This trial is currently recruiting. The enrollment target is 259 participants. The study started on 2012-07-30.
What conditions does trial NCT01660984 study?
This clinical trial studies the following conditions: Medullary Thyroid Cancer.
Who is sponsoring clinical trial NCT01660984?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01660984 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medullary Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RECRUITING · Phase 1
-
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02361320 · 259 participants · NA
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
- NCT06797258 · 259 participants · NA
FlexHD® Pliable Investigation in Implant-Based Breast Reconstruction
- NCT06990425 · 259 participants · NA
CLOSM Trial: Groin Closure Using Layered Option for Suture Material
- NCT07399977 · 259 participants · NA
Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI